IXICO plc (AIM:IXI)
8.87
+0.22 (2.60%)
May 26, 2026, 3:44 PM GMT
IXICO Revenue
IXICO had revenue of 3.95M GBP in the half year ending March 31, 2026, with 55.59% growth. This brings the company's revenue in the last twelve months to 7.28M, up 13.04% year-over-year. In the fiscal year ending September 30, 2025, IXICO had annual revenue of 6.53M with 13.32% growth.
Revenue (ttm)
7.28M
Revenue Growth
+13.04%
P/S Ratio
2.59
Revenue / Employee
92.09K
Employees
79
Market Cap
18.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 6.53M | 768.00K | 13.32% |
| Sep 30, 2024 | 5.77M | -899.00K | -13.49% |
| Sep 30, 2023 | 6.67M | -1.98M | -22.89% |
| Sep 30, 2022 | 8.64M | -547.00K | -5.95% |
| Sep 30, 2021 | 9.19M | -342.00K | -3.59% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 9.76M |
| SkinBioTherapeutics | 4.64M |
| Arecor Therapeutics | 1.71M |
| Fusion Antibodies | 1.60M |
| Aptamer Group | 1.38M |
| Oxford BioDynamics | 1.10M |
| ImmuPharma | -69.96K |